S. L. Todhunter

875 total citations
17 papers, 702 citations indexed

About

S. L. Todhunter is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, S. L. Todhunter has authored 17 papers receiving a total of 702 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 13 papers in Epidemiology and 4 papers in Surgery. Recurrent topics in S. L. Todhunter's work include Clostridium difficile and Clostridium perfringens research (17 papers), Microscopic Colitis (13 papers) and Viral gastroenteritis research and epidemiology (4 papers). S. L. Todhunter is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (17 papers), Microscopic Colitis (13 papers) and Viral gastroenteritis research and epidemiology (4 papers). S. L. Todhunter collaborates with scholars based in United Kingdom, Switzerland and Japan. S. L. Todhunter's co-authors include Jane Freeman, Mark H. Wilcox, G. S. Crowther, C. H. Chilton, Scott Nicholson, Simon D. Baines, Christopher Longshaw, Jon J. Vernon, K. Morris and M. H. Wilcox and has published in prestigious journals such as PLoS ONE, Journal of Antimicrobial Chemotherapy and Clinical Microbiology and Infection.

In The Last Decade

S. L. Todhunter

17 papers receiving 693 citations

Peers

Countries citing papers authored by S. L. Todhunter

Since Specialization

Citations

This map shows the geographic impact of S. L. Todhunter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. L. Todhunter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. L. Todhunter more than expected).

Fields of papers citing papers by S. L. Todhunter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. L. Todhunter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. L. Todhunter. The network helps show where S. L. Todhunter may publish in the future.

Co-authorship network of co-authors of S. L. Todhunter

This figure shows the co-authorship network connecting the top 25 collaborators of S. L. Todhunter. A scholar is included among the top collaborators of S. L. Todhunter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. L. Todhunter. S. L. Todhunter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Efficacy of vancomycin extended-dosing regimens for treatment of simulatedClostridium difficileinfection within anin vitrohuman gut model 2016 ·Journal of Antimicrobial Chemotherapy ·G. S. Crowther, C. H. Chilton, Christopher Longshaw, S. L. Todhunter, (unknown), Jon J. Vernon, Andreas Karas, Mark H. Wilcox	13
2	Efficacy of alternative fidaxomicin dosing regimens for treatment of simulatedClostridium difficileinfection in anin vitrohuman gut model 2015 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, G. S. Crowther, S. L. Todhunter, Helen Ashwin, Christopher Longshaw, Alexei Karas, Mark H. Wilcox	23
3	Recurrence of dual-strainClostridium difficileinfection in anin vitrohuman gut model 2015 ·Journal of Antimicrobial Chemotherapy ·G. S. Crowther, C. H. Chilton, S. L. Todhunter, Scott Nicholson, Jane Freeman, Mark H. Wilcox	4
4	Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model 2014 ·Journal of Antimicrobial Chemotherapy ·G. S. Crowther, C. H. Chilton, S. L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines, M. H. Wilcox	35
5	Development and Validation of a Chemostat Gut Model To Study Both Planktonic and Biofilm Modes of Growth of Clostridium difficile and Human Microbiota 2014 ·PLoS ONE ·G. S. Crowther, C. H. Chilton, S. L. Todhunter, Scott Nicholson, Jane Freeman, Simon D. Baines, Mark H. Wilcox	39
6	SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model 2014 ·Journal of Antimicrobial Chemotherapy ·Simon D. Baines, G. S. Crowther, Jane Freeman, S. L. Todhunter, Richard Vickers, Mark H. Wilcox	35
7	Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes 2014 ·Clinical Microbiology and Infection ·Jane Freeman, Jon J. Vernon, K. Morris, Scott Nicholson, S. L. Todhunter, Christopher Longshaw, Mark H. Wilcox	217
8	Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection 2014 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, G. S. Crowther, S. L. Todhunter, Scott Nicholson, Jane Freeman, Laurent Chesnel, Mark H. Wilcox	25
9	Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure 2013 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, G. S. Crowther, Jane Freeman, S. L. Todhunter, Scott Nicholson, Christopher Longshaw, Mark H. Wilcox	41
10	Mixed infection by Clostridium difficile in an in vitro model of the human gut 2013 ·Journal of Antimicrobial Chemotherapy ·Simon D. Baines, G. S. Crowther, S. L. Todhunter, Jane Freeman, C. H. Chilton, Warren N. Fawley, Mark H. Wilcox	12
11	In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection 2013 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, G. S. Crowther, Simon D. Baines, S. L. Todhunter, Jane Freeman, Hans H. Locher, Athanasios E. Athanasiou, Mark H. Wilcox	53
12	Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model 2013 ·Journal of Antimicrobial Chemotherapy ·Simon D. Baines, C. H. Chilton, G. S. Crowther, S. L. Todhunter, Jane Freeman, M. H. Wilcox	15
13	Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model 2012 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, Jane Freeman, G. S. Crowther, S. L. Todhunter, Mark H. Wilcox	25
14	Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model 2012 ·Journal of Antimicrobial Chemotherapy ·Jane Freeman, Miriam Marquis, G. S. Crowther, S. L. Todhunter, Warren N. Fawley, C. H. Chilton, Greg Moeck, Dario Lehoux, Mark H. Wilcox	14
15	Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection 2012 ·Journal of Antimicrobial Chemotherapy ·G. S. Crowther, Simon D. Baines, S. L. Todhunter, Jane Freeman, C. H. Chilton, M. H. Wilcox	96
16	Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model 2012 ·Journal of Antimicrobial Chemotherapy ·C. H. Chilton, Jane Freeman, G. S. Crowther, S. L. Todhunter, Scott Nicholson, M. H. Wilcox	24
17	Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model 2011 ·Journal of Antimicrobial Chemotherapy ·Simon D. Baines, (unknown), (unknown), S. L. Todhunter, (unknown), Joanne K. Hobbs, Jane Freeman, A. M. Lovering, (unknown)	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact